Fisogatinib
Tier C — Watch / tradeFisogatinib
Targets：FGFR4
Indications (approved)：Hepatocellular carcinoma
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| Fisogatinib-001 | 1538605-06-9 | 2-chloro-6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazoline |
| Fisogatinib-002 | 1707289-89-1 | (3S,4S)-4-azidotetrahydro-2H-pyran-3-amine hydrochloride |
| Fisogatinib-003 | 1707289-88-0 | N-((3S,4S)-4-azidotetrahydro-2H-pyran-3-yl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-amine |
| Fisogatinib-004 | 1707289-90-4 | (3S,4S)-N3-(6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)tetrahydro-2H-pyran-3,4-diamine |
Frequently asked questions
What are the approved indications of Fisogatinib?
Approved indications include: Hepatocellular carcinoma.
When does the Fisogatinib patent expire?
No public expiry year is available for Fisogatinib yet; this page updates once verified.
How many synthesis routes are recorded for Fisogatinib?
1 synthesis routes are recorded; the shortest is 3 steps with 0.041 g (Fisogatinib) total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Fisogatinib intermediates?
All intermediates in Fisogatinib routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Fisogatinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-07